Global Markets Direct’s, ‘Metastatic Ovarian Cancer – Pipeline Review, H2 2015′, provides an overview of the Metastatic Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Ovarian Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Ovarian Cancer - Overview 8
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis 9
Metastatic Ovarian Cancer - Therapeutics under Development by Companies 10
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 11
Metastatic Ovarian Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Metastatic Ovarian Cancer - Products under Development by Companies 14
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes 15
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development 16
Cellceutix Corporation 16
Eisai Co., Ltd. 17
F. Hoffmann-La Roche Ltd. 18
Immune Design Corp. 19
Millennium Pharmaceuticals, Inc. 20
Natco Pharma Limited 21
Northwest Biotherapeutics, Inc. 22
Sumitomo Dainippon Pharma Co., Ltd. 23
VG Life Sciences, Inc. 24
Metastatic Ovarian Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
DCVax-Direct - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
DCVax-L - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs for Metastatic Ovarian Cancer - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-7449 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
emactuzumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
G-305 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
hydroxychloroquine + sorafenib tosylate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KM-3174 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LV-305 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NRCAN-019 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
orteronel - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SM-276001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Vaccine for Oncology - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Metastatic Ovarian Cancer - Recent Pipeline Updates 55
Metastatic Ovarian Cancer - Dormant Projects 74
Metastatic Ovarian Cancer - Discontinued Products 75
Metastatic Ovarian Cancer - Product Development Milestones 76
Featured News & Press Releases 76
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables

Number of Products under Development for Metastatic Ovarian Cancer, H2 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2015 16
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2015 17
Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 18
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2015 19
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 20
Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2015 21
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2015 22
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 23
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Assessment by Combination Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2015 55
Metastatic Ovarian Cancer - Dormant Projects, H2 2015 74
Metastatic Ovarian Cancer - Discontinued Products, H2 2015 75

List of Figures

Number of Products under Development for Metastatic Ovarian Cancer, H2 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 12
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Top 10 Targets, H2 2015 27
Number of Products by Stage and Top 10 Targets, H2 2015 27
Number of Products by Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 29
Number of Products by Top 10 Routes of Administration, H2 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 31
Number of Products by Top 10 Molecule Types, H2 2015 33
Number of Products by Stage and Top 10 Molecule Types, H2 2015 33